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tions in  transcatheter  treatment  of  patent  ductus  arteriosus  (PDA).  Transcatheter  PDA  closure  is
the standard  of  care  in  most  cases  and  PDA  closure  is  indicated  in  any  patient  with  signs  of  left
ventricular  volume  overload  due  to  a  ductus.  In  cases  of  left-to-right  PDA  with  severe  pulmonary
arterial hypertension,  closure  may  be  performed  under  speciﬁc  conditions.  The  management  of
clinically silent  or  very  tiny  PDAs  remains  highly  controversial.  Techniques  have  evolved  and  the
Abbreviations: ADO, Amplatzer Duct Occluder; ADO II, second-generation Amplatzer Duct Occluder; ADO II AS, second-generation
Amplatzer Duct Occluder with additional sizes; MPA, main pulmonary artery; PAH, pulmonary arterial hypertension; PDA, patent ductus
rteriosus.
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transcatheter  approach  to  PDA  closure  is  now  feasible  and  safe  with  current  devices.  Coils
and the  Amplatzer  Duct  Occluder  are  used  most  frequently  for  PDA  closure  worldwide,  with
a high  occlusion  rate  and  few  complications.  Transcatheter  PDA  closure  in  preterm  or  low-
bodyweight  infants  remains  a  highly  challenging  procedure  and  further  device  and  catheter
design development  is  indicated  before  transcatheter  closure  is  the  treatment  of  choice  in  this
delicate patient  population.  The  evolution  of  transcatheter  PDA  closure  from  just  40  years  ago
with 18  F  sheaths  to  device  delivery  via  a  3  F  sheath  is  remarkable  and  it  is  anticipated  that
further improvements  will  result  in  better  safety  and  efﬁcacy  of  transcatheter  PDA  closure
techniques.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  L’objectif  de  cette  revue  de  la  littérature  est  de  décrire  l’histoire  de  la  fermeture
percutanée  du  canal  artériel,  ainsi  que  les  techniques  actuelles  et  les  perspectives  d’avenir.
La fermeture  percutanée  est  la  méthode  de  choix  dans  la  grande  majorité  des  cas.  Elle  est
indiquée  chez  tous  les  patients  ayant  des  signes  de  surcharge  volumique  du  ventricule  gauche
par le  shunt  artériel.  En  cas  d’hypertension  pulmonaire,  la  fermeture  du  canal  est  envisagée  à
condition que  le  shunt  soit  toujours  exclusivement  gauche-droit  et  sous  certaines  conditions.
Des controverses  perdurent  quant  à  la  prise  en  charge  des  très  petits  canaux  artériels  ou  des
canaux artériels  persistants  mais  cliniquement  silencieux.  Les  progrès  techniques  constants
réalisés ces  dernières  années  ont  rendu  cette  procédure  sûre  avec  les  dispositifs  actuels.  Les
coils et  la  prothèse  d’Amplatz  ADO  sont  actuellement  les  dispositifs  les  plus  utilisés  à  travers
le monde,  avec  peu  de  complications  et  un  fort  taux  de  succès  de  la  procédure.  La  fermeture
percutanée  du  canal  artériel  chez  les  nourrissons  prématurés  ou  de  faible  poids  reste  cependant
techniquement  difﬁcile  et  le  développement  de  nouveaux  matériels  miniaturisés  reste  néces-
saire pour  considérer  l’approche  percutanée  comme  le  traitement  de  première  intention  dans
cette population  de  patients  particulièrement  fragiles.  Les  remarquables  évolutions  techniques
dans la  fermeture  percutanée  du  canal  artériel  depuis  40  ans  ont  permis  de  passer  progressive-
ment des  introducteurs  18  French  à  du  matériel  miniaturisé  3  ou  4  French  utilisé  en  pratique
quotidienne.  Cette  dynamique  constante  permettra  à  l’avenir  d’améliorer  encore  davantage  la
faisabilité  et  la  sécurité  de  cette  procédure  en  toute  situation.





















Since  the  ﬁrst  surgical  patent  ductus  arteriosus  (PDA)  closure
by  Gross  and  Hubbard  in  1939  and  the  later  transcathe-
ter  PDA  closure  by  Portsmann  et  al.  in  1967,  there  have
been  many  signiﬁcant  developments  in  the  devices  used  to
close  a  PDA  [1,2].  In  the  past  20  years,  transcatheter  closure
has  become  the  leading  approach  to  closure  of  most  PDAs
[3].  This  review  aims  to  describe  past  history,  present  tech-
niques  and  future  directions  in  transcatheter  treatment  of
PDA.
Patent ductus arteriosus
The  ductus  arteriosus  is  a  vascular  structure  that  connects
the  left  pulmonary  artery  near  its  origin  to  the  descend-
ing  aorta  just  after  the  left  subclavian  artery;  it  is  an
essential  foetal  structure  that  closes  spontaneously  in  about
90%  of  full-term  infants  during  the  ﬁrst  48  hours  of  life.
Persistent  patency  of  the  PDA  beyond  a  few  weeks  is  con-
sidered  abnormal  and  is  mainly  encountered  in  neonates
with  ventilatory  or  circulatory  abnormalities  or  in  pre-
mature  infants.  Formally  speaking,  PDA  is  considered  a
form  of  congenital  heart  disease,  deﬁned  as  a  persistent
patency  beyond  the  third  month  of  life  in  term  infants




Peart  diseases.  In  the  adult  PDA  is  usually  an  isolated
esion.
In  full-term  children,  the  reported  incidence  of  PDA
s  approximately  1  per  2000  live  births,  accounting  for
—10%  of  all  congenital  heart  diseases  [5].  However,  addi-
ion  of  the  ‘silent’  PDA  dramatically  increases  its  incidence
o  1  per  500  live  births  [6].  PDA  is  a common  prob-
em  in  premature  neonates  and  extremely-low-birthweight
nfants,  being  found  in  65%  of  neonates  with  a  birth-
eight  ≤  1000  g,  and  is  associated  with  various  neonatal
orbidities  [7].  The  female  to  male  ratio  is  2:1  in  most
eports  [4].
Due  to  several  genetic  or  environmental  factors,  the
uctus  may  remain  patent,  causing  a  left-to-right  shunt  at
he  arterial  level,  pulmonary  overcirculation  and  left  heart
olume  overload.  The  magnitude  of  shunting  depends  on
he  ﬂow  resistance  of  the  ductus  and  the  pressure  gradi-
nt  between  aorta  and  pulmonary  arteries.  This  gradient  is
ynamic,  systolic  and  diastolic,  depending  on  cardiac  out-
ut  and  both  systemic  and  pulmonary  vascular  resistances
8,9].  PDA  has  a  broad  spectrum  of  clinical  manifestations,
arying  from  asymptomatic  heart  murmur  to  congestive
eart  failure  or  Eisenmenger’s  syndrome.  The  natural  history
f  the  PDA  largely  depends  upon  its  size,  the  magni-
ude  of  the  shunt  and  the  pulmonary  vascular  resistances.


















































































































symptomatic  for  years.  However,  historical  series  have
hown  that  chronic  volume  overload  may  ultimately  lead
o  severe  complications,  such  as  congestive  heart  failure,
trial  arrhythmias,  irreversible  hypertensive  pulmonary  vas-
ular  disease,  endarteritis  and,  rarely,  ductus  aneurysm  or
cute  aortic  dissection  [9—14].
PDA  can  be  managed  by  medical,  surgical  or  transcat-
eter  treatment.  Non-selective  cyclo-oxygenase  inhibitors
ave  received  the  US  Food  and  Drug  Administration’s
pproval  for  the  pharmacological  treatment  of  PDA;  their
se  results  in  successful  PDA  closure  in  75—93%  of  cases  [15].
owever,  this  efﬁcacy  has  to  be  balanced  with  their  signif-
cant  potential  adverse  effects  on  other  organ  perfusion.
oreover,  indications  for  treatment  remain  a  controver-
ial  topic,  as  40%  of  PDAs  close  spontaneously,  even  in
xtremely-low-birthweight  neonates.  Thus,  although  efﬁ-
acious  for  medical  closure  of  the  PDA  in  the  premature
nfant,  a  careful  assessment  of  risk/beneﬁt  is  critical
hen  deciding  whether  cyclo-oxygenase  inhibitors  should
e  used  and  this  decision  must  be  individualized  to  the
articular  patient.  Guidelines  for  managing  PDA  in  very-
ow-birthweight  infants  have  been  proposed  to  clarify  this
ssue  [16].  Surgical  closure  is  generally  indicated  in  neonates
n  whom  prostaglandin  inhibitors  have  failed  to  close  the
DA  or  in  cases  where  prostaglandin  inhibitors  are  con-
raindicated.  The  surgical  approach  consists  of  PDA  ligation
r  division  and  is  performed  via  left  posterior  lateral
horacotomy  or,  in  some  experienced  hands,  by  a  mini-
ally  invasive  technique  via  video-assisted  thoracoscopic
urgery  [17].  In  older  patients,  surgical  closure  remains
he  treatment  of  choice  in  the  rare  patients  with  a duc-
us  too  large  for  device  closure  or  with  unsuitable  anatomy,
uch  as  aneurysmal  ductus  [9].  In  most  reports,  surgical
DA  closure  allows  a  complete  closure  rate  of  94—100%
ith  a  0—2%  mortality  rate  [18,19].  The  most  common
omplications  of  surgical  ductal  intervention  include  pneu-
othorax,  bleeding  and  recurrent  laryngeal  nerve  injury.
lthough  extremely  efﬁcacious  and  safe  for  the  closure
f  PDAs,  the  surgical  approach  may  be  associated  with
reater  morbidity  and  postoperative  pain  than  transcat-
eter  techniques  and  these  factors  have  been  the  most
ommon  reasons  that  percutaneous  PDA  closure  has  rapidly
ecome  the  ﬁrst  choice  for  PDA  closure  in  the  appropriate
atient.
he past: proof of the concept
DA  was  the  ﬁrst  congenital  heart  disease  treated  by  percu-
aneous  intervention.  In  1966,  Portsmann  et  al.  performed
he  ﬁrst  transcatheter  closure  of  a  PDA  without  thoraco-
omy  in  a  17-year-old  boy  [2].  The  device  used  was  an
valon  plug,  introduced  through  an  18  F  femoral  arterial
heath  and  travelling  on  a  percutaneously  laid  transduc-
al  arteriovenous  guide  wire.  Based  on  this  technique,
DA  closure  was  performed  in  197/208  patients  (94.7%,
ge  5—62  years)  between  1967  and  1985.  The  reduced
rocedural  time,  lack  of  need  for  a thoracotomy  and
horter  length  of  hospital  stay  observed  with  this  approach
upported  further  developments  of  the  procedure  [20].
owever,  the  major  concern  regarding  the  initial  ‘Ports-
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elivery  sheath,  limiting  its  use  in  paediatric  patients.  In
976,  Rashkind  et  al.  developed  a  transcatheter  technique
uitable  for  use  in  small  children,  leading  to  the  ﬁrst  success-
ul  report  2 years  later  in  an  infant  weighing  3500  g [21].  The
ustom-fabricated  prototype  closure  system  consisted  of  a
ingle-foam-disc  hooked  prosthesis  connected  to  a  pin-eye-
leeve  attachment-release  mechanism.  The  system  was  then
edesigned  and  a  hookless  double-disc  system  with  a  pin-
ye-sleeve  attachment-release  mechanism  was  developed
Rashkind  PDA  Occluder  System).  Two  polyurethane  discs
ounted  on  opposing  three-  or  four-arm  spines  were  assem-
led,  resembling  two  umbrellas.  The  ﬁrst  clinical  results  in
46  patients  treated  with  the  Rashkind  PDA  Occluder  System
ere  published  in  1987.  Successful  closure  was  accom-
lished  in  94  patients  (66%),  with  device  embolization  in
9  patients  (15%)  [22].  Although  the  methods  introduced
y  Portsmann  et  al.  and  Rashkind  et  al.  showed  advan-
ages  over  surgical  closure,  the  delivery  catheter  remained
arge  and  bulky,  limiting  its  widespread  use.  Portsmann’s
valon  plug  required  a  13  F  to  28  F  femoral  arterial  access
nd  Rashkind’s  double-disc  device  was  delivered  through
n  8  F  to  11  F  femoral  venous  access.  Additionally  and
mportantly,  the  success  rates  for  transcatheter  PDA  clo-
ure  using  these  two  initial  devices  were  still  signiﬁcantly
orse  than  results  reported  with  the  more  standard  surgical
pproach.
Sideris  et  al.  developed  a  self-adjustable  PDA  device
hat  was  modiﬁed  into  a  buttoned  device  that  could  be
elivered  through  a  7  F  sheath.  The  adjustable  length
f  the  loop  allowed  closure  of  all  types  of  and  large
DAs  [23]. Other  similar  devices,  such  as  the  Botallo
ccluder  and  the  Lock  Clamshell  device,  were  developed
nd  transcatheter  PDA  occlusion  became  widely  avail-
ble  and  was  used  as  an  alternative  to  surgery  in  the
arly  1990s  [24].  These  devices  were  gradually  abandoned
ecause  of  a  high  incidence  of  residual  leak  and  subse-
uent  persistent  risk  of  endarteritis,  device  instability  or
ther  major  complications  [25—27].  Thus,  despite  initial
idespread  enthusiasm,  reproducible  and  safe  percutaneous
DA  closure  proved  to  be  more  difﬁcult  than  initially  esti-
ated.
Further  research  was  done  to  develop  a  device  that  could
ddress  many  of  the  problems  of  the  earlier  devices.  Some
f  the  important  features  that  were  still  not  achieved  were
elivery  of  the  device  via  a  small-sized  catheter,  reposition-
ng  of  the  device  multiple  times  until  ultimately  released,
etrieval  of  the  device  easily  if  necessary,  and  the  ability
o  allow  for  complete  closure  without  causing  any  aortic  or
ulmonary  artery  obstruction  or  damage  [28]. The  introduc-
ion  of  embolization  coils  and  the  Amplatzer  Duct  Occluder
ADO,  Saint  Jude  Medical,  Minnesota)  addressed  many  of
hese  concerns.
Since  the  initial  reports,  the  success  rates  of  several
echniques  of  duct  closure  with  embolization  coils  have
ontinued  to  improve  [29,30].  The  immediate  success  rate
anged  from  75%  to  95%  and  the  rate  of  closure  was  inversely
elated  to  the  size  of  the  ductus  and  dependent  on  the
xperience  of  the  operator.  Additionally,  the  coil  technique,
lthough  inexpensive  and  feasible  via  small  catheters,  was
ot  suitable  for  all  ducts  and  was  associated  with  a  higher
han  acceptable  rate  of  coil  embolization,  particularly  in  the
etting  of  the  large  ductus.
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tTranscatheter  PDA  closure  
The  ADO  was  introduced  to  address  many  of  the  deﬁcien-
cies  of  coil  embolization  techniques.  It  is  a  self-expandable
repositionable  mushroom-shaped  device  made  from  a  0.004-
inch-thick  nitinol  wire  mesh  with  Dacron  patches  within.  In
1998,  Masura  et  al.  reported  the  initial  successful  expe-
rience  with  the  ADO  in  24  patients  using  an  antegrade
approach  and  a  transvenous  6  F  delivery  sheath  [31]. Pass
et  al.  later  conﬁrmed  these  results  in  a  multicentre  trial  in
the  USA  that  conﬁrmed  the  safety  and  effectiveness  of  ADO
use  for  transcatheter  PDA  closure.  ADO  and  coils  are  cur-
rently  the  preferred  technique  for  catheter  closure  of  PDA
worldwide,  with  most  operators  using  coils  for  smaller  ducts
(in  which  the  likelihood  of  success  is  great)  and  the  ADO  for
larger  PDAs.
The present: daily practice in the
catheterization lab
Transcatheter  PDA  occlusion  has  become  the  treatment  of
choice  for  most  PDAs  in  term  infants,  children  and  adults  [3].
Although  age  and  size  are  not  a  consideration  when  planning
surgical  closure,  transcatheter  closure  is  usually  delayed,  if
feasible,  until  later  in  the  ﬁrst  year  of  life,  mostly  because
of  the  risks  of  peripheral  vascular  injury.
Precatheterization care
Most  of  these  patients  have  no  associated  structural  heart
disease.  The  clinical  examination  demonstrates  the  PDA
continuous  murmur  in  the  expected  location.  The  elec-
trocardiogram  is  often  normal.  Active  infection  is  ruled
out.  Transthoracic  echocardiography  aims  to  identify  any
potential  associated  lesions,  to  assess  left  ventricular  vol-
ume  diameters  and  function,  to  assess  PDA  size  and,
ﬁnally,  to  assess  pulmonary  arterial  pressure.  The  echocar-
diogram  is  very  useful  in  determining  if  PDA  closure  is,
in  fact,  indicated.  Although  it  was  previously  believed
that  all  PDAs  identiﬁed  should  be  closed,  with  more
relaxed  recommendations  regarding  subacute  bacterial
endocarditis  prophylaxis  in  the  setting  of  the  ductus,  small
haemodynamically-insigniﬁcant  PDAs  with  no  evidence  for
left  atrial  or  left  ventricular  enlargement  are  often  not
closed.
Angiographical classiﬁcation
Following  a  brief  assessment  of  the  haemodynamics,  PDA
closure  always  begins  with  an  aortogram  to  precisely  assess
the  aortic  arch  and  PDA  characteristics,  as  the  ductus
arteriosus  may  persist  in  a  wide  variety  of  sizes  and  con-
ﬁgurations  (Fig.  1).  Krichenko  et  al.  described  a  useful
angiographical  classiﬁcation  for  guidance  of  transcatheter
PDA  closure  [32].  Ductal  anatomy  in  the  lateral  projection
is  classiﬁed  into  ﬁve  categories:  type  A  is  a  conical  duc-
tus,  with  a  well-deﬁned  aortic  ampulla  and  constriction  at
its  pulmonary  end;  type  B  is  a  large  and  very  short  ductus,
mimicking  an  aortopulmonary  window-like  structure;  type
C  is  a  tubular  duct,  of  varying  length,  without  any  constric-
tion  at  its  pulmonary  end;  type  D  is  more  complex,  with
multiple  constrictions  on  the  ductus;  type  E  is  an  elongated
ductus,  frequently  seen  in  ex-premature  babies.  This  initial
d
r
buctal anatomy in the lateral projection is classiﬁed into ﬁve cate-
ories.
ngiography  is  performed  with  a  4  F  or  5  F  pigtail  catheter
ositioned  in  the  proximal  descending  aorta  in  the  straight
ateral  view.  Other  projections  may  be  helpful,  such  as  30◦
ight  anterior  oblique  projections  in  the  left-sided  aortic
rch,  30◦ left  anterior  oblique  projections  in  the  right-sided
ortic  arch  and,  eventually,  a combined  left  anterior  oblique
0◦,  cranial  30◦ to  open  up  the  pulmonary  artery  bifurcation
nd  show  the  proximal  left  pulmonary  artery  (for  dextrocar-
ia,  it  is  the  right  anterior  oblique  equivalent).
oil occlusion
oil  occlusion  is  a  safe  and  effective  procedure  for  small
DA  closure  (Fig.  2).  According  to  the  3:1  principle,  the  coil
s  the  chosen  strategy  if  the  total  ductal  length  is  more  than
hree  times  the  narrowest  diameter  of  the  PDA  [33]. Others
ave  simply  used  minimal  ductal  diameter  <  1.5—2  mm  as  an
ndication  for  coil  implantation,  as  device  implantation  in
uch  small  PDAs  can  be  challenging.  Coils  are  restricted  to
mall  Krichenko  type  A1  or  E  PDAs,  which  constitute  the
ast  majority  of  PDAs.  Residual  shunting  and  coil  emboliza-
ion  are  more  likely  to  occur  if  used  in  shorter  ducts  or  in
ucts  >  3  mm  diameter  [34].The  most  commonly  used  approach  is  an  arterial  ret-
ograde  one,  but  delivery  of  a  coil  to  the  ductus  has
een  described  for  both  the  anterograde  and  retrograde
126  A.-E.  Baruteau  et  al.
Figure 2. Coil occlusion of a patent ductus arteriosus (PDA).
A. Initial aortography in lateral projection shows a small PDA.
B. Selective hand-injected angiography through an end-hole
catheter just in front of the aortic ampulla of the ductus. C. The coil
is advanced to the main pulmonary artery and carefully deployed



























Figure 3. Occlusion of a patent ductus arteriosus (PDA) with an
Amplatzer duct occluder (ADO) device. A. Initial aortography show
left-to-right shunting through a large Krichenko type A1 PDA. B. A
delivery sheath is advanced transvenously through the ductus to
the descending aorta. C. The retention skirt of the ADO device is
ﬁrst deployed in the descending aorta and then pulled back into





















relivery, a small hand injection through the end-hole catheter doc-
ments good positioning of the coil and absence of residual leak.
pproaches.  Femoral  access  is  required  in  all  patients  and
n  appropriately  sized  sheath  is  utilized  to  allow  for  an  ade-
uate  angiogram  for  anatomical  deﬁnition  of  the  ductus.
n  initial  angiography  is  performed  with  a  4  F  or  5  F  pig-
ail  catheter  positioned  in  the  proximal  descending  aorta
n  lateral  and  30◦ right  anterior  oblique  projections  [35].
his  injection  can  be  completed  by  selective  hand-injected
ngiography  through  an  end-hole  catheter  just  in  front  of
he  aortic  ampulla  of  the  ductus,  although  a  power  injec-
ion  is  preferred  for  more  clear  anatomical  deﬁnition.  The
DA  is  crossed  by  a  0.035  inch  wire  and  a  delivery  catheter  is
hen  advanced  over  the  wire  into  the  main  pulmonary  artery
MPA).  Haemodynamic  data  are  recorded  to  conﬁrm  that  the
atheter  tip  is  in  the  MPA.  A  0.035  inch  or  0.038  inch  retriev-
ble  or  ‘free-hand’  coil  is  chosen,  according  to  PDA  size  and
ength.  As  a  general  rule  of  thumb,  a  coil  is  chosen  with  a
oop  diameter  that  is  a  minimum  of  two  times  the  diame-
er  of  the  narrowest  segment  of  the  ductus  and  the  length
f  coil  is  suitable  to  allow  for  four  or  ﬁve  coil  loops.  In  the
resent  era,  non-ferromagnetic  coils  (e.g.  MREYE)  are  more
ommonly  used  than  the  prior  stainless  steel  variety.  The
oil  is  advanced  to  the  MPA  and  carefully  deployed  in  the
DA  under  ﬂuoroscopic  guidance  in  lateral  view.  Half  to  one




ADO placement in the ductus. D. Pigtail aortic angiogram conﬁrms
evice position and absence of residual leak.
nd  the  wire  are  pulled  back  together  until  the  distal  loop
s  at  the  desired  position,  at  the  MPA  side  of  the  ductus.  The
oil  is  then  delivered  with  half  to  one  loop  at  its  pulmonary
nd.  After  10  minutes,  a  small  hand  injection  through  the
nd-hole  catheter  documents  good  positioning  of  the  coil
nd  absence  of  residual  leak.  In  case  of  residual  shunt,  the
ame  technique  is  used  to  recross  the  PDA  and  complete  the
losure  by  placing  an  additional  coil.
evice occlusion
arious  devices  may  be  used  to  occlude  a PDA  according
o  its  morphology  (Fig.  3)  [36—39]. Only  ADO  placement
s  detailed  here,  as  it  is  the  most  commonly  used  device
orldwide.  The  ADO  is  approved  in  children  aged  >  6  months
nd  weighing  >  6  kg;  it  is  placed  with  an  antegrade  approach
nd  is  usually  used  for  PDAs  >  2  mm  with  a  sufﬁcient  aor-
ic  ampulla.  Both  venous  and  arterial  femoral  accesses  are
sually  needed,  for  device  progression  and  simultaneous
ngiographic  controls,  respectively.  After  haemodynamics
ecording,  a  0.035-inch  wire  is  passed  anterograde  from
he  MPA,  across  the  ductus  to  the  abdominal  aorta.  A
elivery  sheath  of  appropriate  size  is  then  advanced  transve-
ously  through  the  ductus  to  the  descending  aorta.  The


















































PTranscatheter  PDA  closure  
under  ﬂuoroscopy  in  the  lateral  view.  The  retention  skirt
is  ﬁrst  deployed  in  the  descending  aorta  and  then  pulled
back  into  the  aortic  ampulla.  Unsheathing  the  device  under
tension  leads  to  ADO  placement  in  the  ductus.  Device  posi-
tion  is  conﬁrmed  by  pigtail  aortic  angiogram  prior  to  ADO
release.
Results and  complications
Incomplete  closure  may  occur  and  has  to  be  treated
by  repeated  procedures,  as  high-velocity  residual  shunt-
ing  may  lead  to  endocarditis  or,  rarely,  haemolysis;  these
complications  are  more  commonly  seen  with  the  use  of
coils.  Embolization  is  also  more  common  with  coils.  How-
ever  the  development  of  controlled-release  coils  in  concert
with  the  development  of  the  ADO  for  closure  of  large  PDAs
has  made  coil  migration  a  relatively  rare  event,  with  a  1%
occurrence  rate  [34].  Embolization  may  occur  to  the  pul-
monary  arteries  or,  rarely,  to  a  systemic  artery  and  requires
transcatheter  or  surgical  retrieval  [40,41].  Device-induced
left  pulmonary  artery  stenosis  or  coarctation  of  the  aorta
may  occur  rarely,  particularly  in  low-bodyweight  patients
with  a  large  PDA  requiring  a  large  device.  Careful  clini-
cal  and  echographical  follow-up  is  the  rule.  In  some  cases,
Doppler  ﬂow  acceleration  may  resolve  spontaneously  with
the  patient’s  growth.  In  others,  obstruction  may  worsen
or  become  clinically  patent,  necessitating  transcatheter
or  surgical  removal  of  the  device.  To  avoid  this  poten-
tial  complication,  aortography  is  always  recommended  after
device  deployment,  prior  to  release  and  following  release
of  the  device.  Even  after  the  device  has  been  released,
it  can  be  percutaneously  retrieved,  if  necessary,  and  the
duct  occluded  using  a  new  device.  In  a  multicentre  ADO  PDA
trial  in  the  USA,  the  ADO  was  implanted  successfully  in  99%
of  patients,  with  an  acute  angiographical  occlusion  in  76%
of  patients.  Complete  shunt  occlusion  was  documented  in
89%  of  patients  on  postcatheterization  day  1  and  in  99.7%
at  1  year  [38].  It  is  important  to  note  that  because  of  the
expected  delayed  closure  of  the  PDA  with  the  ADO  device,
it  is  acceptable  to  leave  the  catheterization  lab  with  resid-
ual  shunting,  as  long  as  the  device  is  in  a  good  position.
However,  when  using  coils  for  PDA  embolization,  it  is  highly
recommended  that  the  catheterization  is  not  completed
until  there  is  angiographical  documentation  of  complete
ductal  closure.  Peripheral  vessels  may  also  be  injured  by
sheaths  [42].
Postcatheterization care
Procedures  are  performed  on  an  outpatient  basis  or  during  a
short  stay  in  hospital.  Clinical  attention  is  given  to  murmur
disappearance  and  vascular  access.  Prophylactic  antibiotics
are  routinely  administered  during  the  procedure.  Postop-
erative  chest  X-ray  and  transthoracic  echocardiography  are
performed  to  conﬁrm  the  good  position  of  the  device  or  coil
and  the  lack  of  residual  shunt.  These  studies  also  serve  as
baseline  data  for  future  evaluations.  Patients  with  no  resid-
ual  shunt,  a  normal  left  ventricle  and  normal  pulmonary
artery  pressure  do  not  require  regular  follow-up  after
6  months.  Patients  with  left  ventricular  dysfunction  and




hould  be  followed  at  intervals  of  1—3  years,  depending  on
everity,  including  evaluation  in  specialized  centres  [3,43].
losure indications and particular cases
onsensually agreed indications for patent
uctus arteriosus closure
losure  of  the  large  haemodynamically-signiﬁcant  PDA
s  established  as  the  standard  of  care  and  can  be  done
afely  using  transcatheter  methods.  PDA  closure  must  be
erformed  in  all  patients  with  signs  of  left  ventricular
olume  overload  and  in  those  with  mild  PAH,  deﬁned
s  pulmonary  arterial  pressures  less  than  two-thirds  of
ystemic  pressures  or  pulmonary  vascular  resistances  less
han  two-thirds  of  systemic  vascular  resistances  [3].  Most
uthorities  believe  that  patients  with  a  continuous  murmur
nd  a  small  PDA,  without  left  ventricular  volume  overload
nd  normal  pulmonary  arterial  pressures,  should  also  be
onsidered  for  percutaneous  closure  to  avoid  further  risks
f  open  PDA-related  complications,  especially  PAH  and
ndocarditis.
linically silent patent ductus arteriosus
he  appropriate  management  of  the  small  clinically  silent
nd  haemodynamically-insigniﬁcant  PDA  remains  controver-
ial  [6,44—46].  According  to  European  Society  of  Cardiology
uidelines,  PDA  closure  should  currently  be  avoided  in  these
atients  [3].  However,  some  authors  support  routine  PDA
losure,  even  in  a  silent  ductus,  to  eliminate  the  lifelong
isk  of  infective  endarteritis  [6,44—47].  However,  as  noted
arlier,  this  risk  is  so  low  that  antibiotic  prophylaxis  is  no
onger  recommended  [3]. Thus,  the  low  risk  of  endarteritis
ust  be  balanced  with  the  small  risks  associated  with  trans-
atheter  PDA  closure.  The  overall  prevalence  of  silent  PDA
s  estimated  at  0.5%  and,  with  increasing  use  of  echocar-
iography,  the  diagnosis  of  small  and  silent  PDA  is  likely  to
ise  [6].  As  nobody  can  truly  balance  the  cumulative  risk  of
DA  closure  procedural  events  and  the  lifetime  risk  of  silent
DA-related  infective  endarteritis,  to  close  or  not  to  close
 silent  PDA  currently  remains  a  controversial  issue  in  daily
ractice.
Loss  of  continuous  murmur  when  previously  heard  may
ead  to  diagnostic  suspicion  of  spontaneous  ductal  spasm.
uctal  spasm  may  also  occur  during  the  process  of  closing
 ductus  and  may  result  in  inaccuracy  in  ductal  measure-
ent.  This  error  may  lead  to  coil  occlusion  or  undersized
evice  occlusion,  with  subsequent  coil/device  embolization
48]. Operators  must  be  aware  of  this  issue  to  avoid  underes-
imating  the  true  ductal  size.  In  fact,  it  may  be  a  reasonable
rule  of  thumb’  to  always  assume  that  the  ductus  being  mea-
ured  is  slightly  larger  than  the  angiographical  measurement
hen  choosing  the  appropriate  ductal  occlusive  device  and
ize.
atent ductus arteriosus in preterm and
ow-bodyweight infants
he  PDA  in  preterm  infants  can  have  signiﬁcant  adverse


















































































































ulmonary  oedema,  prolonged  ventilation,  potential  risks
f  barotrauma,  hyperoxygenation,  bronchopulmonary  dys-
lasia  and  chronic  lung  disease.  Signiﬁcant  left-to-right
hunting  in  preterm  infants  may  also  be  associated  with
ecrotizing  enterocolitis,  intraventricular  haemorrhage  and
eath  [8,49,50].  Current  therapeutic  strategy  includes
edical  treatment  with  non-steroidal  anti-inﬂammatory
gents  [50]  or,  in  refractory  PDA,  surgical  ligation  by  tho-
acotomy,  which  can  be  done  in  the  intensive  care  unit.
ortality  varies  according  to  reports,  but,  in  general,  this  is
 safe  surgery  that  is  rarely  associated  with  signiﬁcant  mor-
idity  or  mortality  in  the  low-birthweight  infant  [51].  Recent
pidemiological  studies  have  shown  a  possible  association
etween  surgical  PDA  ligation  and  impaired  neurological
evelopment,  retinopathy  and  chronic  lung  disease  [49—56].
owever,  given  the  population  of  patients  in  which  surgi-
al  PDA  closure  is  performed,  it  is  difﬁcult  to  know  if  this
ssociation  is  causal  in  nature.
Some  authors  have  reported  their  initial  experience  to
ffer  a  transcatheter  alternative  and  avoid  thoracotomy  and
ts  subsequent  morbidity  [54].  The  transcatheter  approach
s  limited  in  low-bodyweight  infants  because  of  sheath  size,
tiffness  of  the  delivery  system,  protrusion  risk  of  the  device
n  the  left  pulmonary  artery  or  aorta  and  technical  difﬁ-
ulties  for  device  retrieval  if  needed  [57].  Despite  current
anufacturer  recommendations,  ADO  has  been  evaluated
or  ‘off-label’  PDA  closure  in  small  infants,  to  avoid  tho-
acotomy  and  its  subsequent  morbidity  [54].  In  a  large
rench  multicentre  study,  58  infants  weighing  <  6  kg  under-
ent  attempted  PDA  closure  with  the  ADO  [52],  with  an
9.7%  success  rate.  Procedure-related  mortality  and  major
nd  minor  complications  rates  were  1.7%,  6.9%  and  31.0%,
espectively,  leading  the  authors  to  support  surgery  as  the
rst-line  therapy  in  low-bodyweight  infants.  By  contrast,
imas  et  al.  reported  a  more  favourable  experience  in  62
atients,  with  a  94%  success  rate  and  no  deaths  [55]. Fran-
is  et  al.  used  coil  occlusion  with  a  3  F  delivery  system  in
ight  infants  weighing  <  2  kg  (range  930—1800  g)  [58].  Com-
lete  PDA  occlusion  was  obtained  in  all,  without  major
rocedure-  or  access-related  complications,  leading  some
o  consider  coil  occlusion  as  a  feasible  and  safe  strategy
n  selected  symptomatic  preterm  infants  and  in  experi-
nced  hands.  In  another  series  of  infants  weighing  <  4  kg
nder  positive  pressure  ventilation,  transcatheter  PDA  clo-
ure  was  compared  with  surgical  PDA  ligation  in  matched
nfants.  Percutaneous  closure  of  PDA  in  small  infants  on
espiratory  support  was  shown  to  be  equivalent  in  safety
nd  efﬁcacy  and  to  offer  a  shorter  recovery  time  than  sur-
ical  ligation  [53].  Low-bodyweight  infants  with  a  small  and
symptomatic  PDA  have  to  be  considered  for  transcathe-
er  closure  when  they  weigh  >  6  kg.  However,  in  carefully
elected  symptomatic  infants,  especially  if  the  echocar-
iogram  suggests  a  conical  PDA  morphology,  PDA  occlusion
ith  the  ADO  may  be  considered  in  some  children  weigh-
ng  >  2.5  kg  and  in  most  children  weighing  >  4  kg  [55]. This
atter  suggestion  has  to  be  balanced  with  experience  of  the
perators,  as  surgical  PDA  ligation  remains  a  safe  and  feasi-
le  alternative  in  small  infants.  Growing  experience,  further
evelopment  of  miniaturization  materials  and  newer  devices
ill  probably  improve  the  scope  of  transcatheter  PDA  clo-
ure  in  symptomatic  preterm  and/or  low-bodyweight  infants




(A.-E.  Baruteau  et  al.
atent ductus arteriosus with severe
ulmonary arterial hypertension
n  patients  presenting  with  severe  PAH,  deﬁned  as  pul-
onary  arterial  pressures  more  than  two-thirds  of  systemic
ressures  or  pulmonary  vascular  resistances  more  than
wo-thirds  of  systemic  vascular  resistances  but  still  net
eft-to-right  shunt  (Qp:Qs  >  1.5)  or  when  vasoreactive  test-
ng  (preferably  with  nitric  oxide)  or  speciﬁc  PAH  therapies
emonstrate  pulmonary  vascular  reactivity,  PDA  closure
hould  be  considered  [3,8,59]. In  a large  series  of  158
elected  patients  with  isolated  PDA  and  systolic  pulmonary
rtery  pressure  >  50  mmHg,  Zabal  et  al.  showed  that  percu-
aneous  treatment  is  safe  and  effective,  with  immediate
ecrease  of  pulmonary  artery  pressures,  which  continued
o  fall  further  with  time  [60].
However,  long-standing  left-to-right  shunting  in  un-
reated  patients  may  result  in  progressive  increase  in
ulmonary  vascular  resistance.  When  pulmonary  vascular
esistances  exceed  systemic  vascular  resistances,  shunt-
ng  through  the  PDA  reverses  and  become  right-to-left.
n  the  case  of  PDA-related  Eisenmenger’s  pathophysiology,
DA  closure  must  be  avoided.  In  these  cases,  the  duc-
us  may  also  play  an  important  palliative  role  [3].  Indeed,
lthough  reduced  compared  with  the  general  population,
he  life  expectancy  of  Eisenmenger’s  syndrome  patients  is
igniﬁcantly  longer  in  comparison  with  primary  pulmonary
rterial  hypertension.  This  has  been  the  rationale  for  cre-
ting  a  surgical  or  transcatheter  Potts’s  shunt  in  children
ith  suprasystemic  idiopathic  PAH,  perhaps  as  an  attempt  to
irror  the  potential  beneﬁts  of  a  PDA-like  shunt  in  the  set-
ing  of  pulmonary  hypertension,  as  is  seen  in  Eisenmenger’s
yndrome  [61,62].
atent ductus arteriosus in adults
lthough  rare,  isolated  PDA  in  adults  remains  suitable  for
ercutaneous  closure.  Ductal  anatomy  may  differ  from  that
een  in  childhood,  making  transcatheter  closure  technically
uch  more  difﬁcult  than  in  children  [63].  Surgery  may  be
equired  in  some  cases,  especially  if  aneurysmal  [64].  How-
ver,  transcatheter  closure  of  the  arterial  duct  in  adults
s  safe  and  effective  [65,66]  and  the  ADO  remains  the
est-used  device  in  this  age  group  [67].  According  to  duc-
al  anatomy,  various  other  devices,  as  well  as  aortic  stent
rafts  or  the  Amplatzer  muscular  ventricular  septal  defect
ccluder,  have  also  been  reported  [63,68,69]. In  general,
or  the  older  adult  with  a  PDA,  transcatheter  closure  is  the
referred  approach  due  to  the  calciﬁcation  that  is  routinely
een  in  the  older  adult  aorta.  Because  of  this,  surgical  liga-
ion,  as  is  commonly  performed  in  the  young,  is  not  feasible.
ost  such  adult  PDAs  must  be  closed  using  cardiopulmonary
ypass  with  patching  of  the  MPA.  Thus,  any  approach  to  close
n  adult  PDA  in  the  catheterization  laboratory  is  likely  to  be
f  lower  risk  and  safer.
ubular patent ductus arteriosusranscatheter  closure  of  tubular  PDAs  with  insufﬁcient
ortic  ampulla,  especially  in  low-bodyweight  infants  and
dult  patients,  remains  a  challenging  procedure  technically
Fig.  4).  A  proposal  to  use  devices  designed  for  peripheral
Transcatheter  PDA  closure  129



































tas initial aortography showed a tubular, Krichenko type E PDA in a
7 mm Amplatzer Vascular Plug IV device, with an excellent result.
vascular  embolization  has  recently  emerged  and  recent
reports  have  evaluated  the  Amplatzer  Vascular  Plug  (Saint
Jude  Medical,  Minnesota)  and  the  Amplatzer  Vascular  Plug
II  in  different  anatomical  variants,  with  encouraging  results
[70].  In  our  experience  in  22  patients,  the  Amplatzer
Vascular  Plug  IV  was  also  safe  and  efﬁcient  for  tubular  PDA
closure  [Baruteau  et  al.,  in  press].
Patent ductus arteriosus with interrupted
inferior vena cava
Device  closure  of  PDA  with  interrupted  inferior  vena  cava
may  be  challenging,  as  putting  the  delivery  sheath  across
the  ductus  from  the  pulmonary  artery  may  be  dramatically
difﬁcult.  However,  most  of  these  cases  remain  suitable  for
device  occlusion.  Some  authors  have  reported  feasibility  of
PDA  occlusion  with  either  the  ADO  or  a  second-generation
ADO  (ADO  II),  despite  interrupted  inferior  vena  cava  with
azygous  continuation  [71—73].
Postsurgical recanalization of patent ductus
arteriosus
Although  underdetected,  patency  or  recanalization  of  the
arterial  duct  after  surgical  ligation,  detected  by  colour-
ﬂow  Doppler  mapping,  might  be  as  high  as  3.1%  [74];  these
patients  remain  suitable  for  a  transcatheter  intervention.
Crossing  the  PDA  with  the  delivery  sheath  is  the  key  issue
associated  with  the  procedure,  as  previous  surgical  ligation
can  make  recrossing  of  the  ductus  challenging.  Complete
occlusion  is  generally  obtained  by  ADO  or  coil  implantation.
The future: new devices and perspectives
New devices: the Amplatzer Duct Occluder II
and II ASThe  ADO  II  was  released  in  2007  and  obtained  European  CE
mark  approval  in  2009,  with  additional  sizes  (ADO  II  AS)  avail-




tlt patient; the PDA was closed via a retrograde approach using a
rovided  by  Thanopoulos  et  al.  and  Bhole  et  al.,  showing
ood  safety  and  a  high  occlusion  rate  [75,76]. The  ADO  II
s  a  self-expanding  self-cantering  retrievable  device.  Device
izes  correspond  to  the  connecting  waist  diameter,  ranging
rom  3  to  6  mm,  with  two  available  lengths  of  4  and  6  mm.
he  ADO  II  is  more  ﬂexible  than  the  ADO  and  can  be  delivered
hrough  a 4 F  or  5  F  sheath  or  catheter.  Preliminary  results
re  encouraging,  without  protrusion  reported  [36,70]. The
etention  discs  are  laid  ﬂat  against  the  walls  of  the  pul-
onary  artery  and  aorta.  However,  device  embolization  has
een  reported  [70].  The  symmetrical  design  of  the  ADO  II
ermits  its  delivery  by  either  a venous  or  arterial  approach.
he  occlusion  rate  is  high,  with  <  2%  residual  shunting  at
ostprocedural  day  1  [70]. However,  the  ADO  II  and  ADO  II
S  devices  have  not  been  widely  used  to  date.
erspectives
ercutaneous  PDA  closure  in  preterms  and  low-bodyweight
nfants  remain  the  main  challenge.  A  new  device  generation
s  expected,  with  shorter  devices,  a large  choice  of  avail-
ble  diameters  and  systems  suitable  for  a  3  F  or  4  F  sheath.
n  a  series  of  55  preterm  infants  considered  for  PDA  clo-
ure  reported  by  Trefz  et  al.,  the  mean  patient  weight  was
018  g  (560—2400  g)  and  the  mean  ductal  length  was  4.1  mm
2.5—5.3  mm).  Mean  diameters  of  the  ductus,  left  pulmonary
rtery  and  descending  aorta  were  2.2  mm  (1.5—3.6  mm),
 mm  (1.5—4.5  mm)  and  4.3  mm  (2.7—7.8  mm),  respectively
77]. While  low  bodyweight  is  an  independent  risk  factor
or  adverse  events  during  cardiac  catheterization  of  infants,
pecial  attention  will  be  given  to  the  management  of  these
atients  in  our  catheterization  laboratories  [65].
As  can  be  seen  from  this  review,  there  have  been  pro-
ound  and  signiﬁcant  improvements  in  the  transcatheter
pproach  to  the  PDA.  In  the  present  era,  virtually  any  size
f  patient  can  have  their  PDA  closed  via  a  transcathe-
er  approach.  However,  a  few  important  questions  remain.
irst,  there  is  the  question  of  the  small  ductus  with  a  mur-
ur  but  no  increased  volume  on  echocardiography.  Although
ost  agree  that  the  ‘silent’  duct  should  not  be  closed,

































































ery  small  ductus  using  echocardiography  and  other  imaging
odalities  gives  the  cardiologist  the  ability  to  determine
he  actual  haemodynamic  burden  of  a  very  small  shunt.  Are
atients  with  a  Qp:Qs  of  1.2:1  really  at  haemodynamic  risk
nd  is  that  risk  greater  than  the  small  risks  associated  with
ranscatheter  closure?  The  answers  are  still  unclear.  Sec-
nd,  questions  remain  regarding  which  small  infants  should
ndergo  PDA  closure  and  how  this  should  be  achieved.
lthough  some  studies  have  shown  that  transcatheter  clo-
ure  is  feasible  and  useful  in  even  the  smallest  of  infants,
here  are  certainly  many  irrefutable  catheterization-related
isks  as  the  patient  size  gets  smaller.  As  catheters  and  deliv-
ry  systems  become  increasingly  miniaturized,  the  threshold
or  transcatheter  approaches  for  these  small  patients  will
e  lowered.  Finally,  although  newer  ﬂuoroscopic  laborato-
ies  use  markedly  lower  radiation  dose  than  in  the  recent
ast,  it  is  clear  that  further  attempts  at  these  procedures
ith  either  a  lower  ﬂuoroscopy  dosage  or  perhaps  even  no
uoroscopy  (with  guidance  via  echocardiography  or  other
odalities)  will  clearly  further  improve  the  safety  of  PDA
losure.
onclusion
ranscatheter  PDA  closure  is  the  standard  of  care  in  most
ases  and  PDA  closure  is  indicated  in  any  patient  with  signs  of
eft  ventricular  volume  overload  due  to  a  ductus.  In  cases  of
eft-to-right  PDA  with  severe  PAH,  closure  may  be  performed
nder  speciﬁc  conditions.  Management  of  clinically  silent
r  very  tiny  PDAs  remains  highly  controversial.  Techniques
ave  evolved  and  the  transcatheter  approach  to  PDA  clo-
ure  is  now  feasible  and  safe  with  current  devices.  Coils  and
DOs  are  used  most  frequently  for  PDA  closure  worldwide,
ith  a  high  occlusion  rate  and  few  complications.  Trans-
atheter  closure  of  the  PDA  in  preterm  or  low-bodyweight
nfants  remains  a  highly  challenging  procedure  and  further
evice  and  catheter  design  development  is  indicated  before
ranscatheter  closure  is  the  treatment  of  choice  in  this  deli-
ate  patient  population.  The  evolution  of  transcatheter  PDA
losure  from  just  40  years  ago  with  18  F  sheaths  to  device
elivery  via  a  3  F  sheath  is  remarkable  and  it  is  anticipated
hat  further  improvements  will  improve  the  safety  and  efﬁ-
acy  of  transcatheter  PDA  closure  techniques.
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